The therapeutic effects of X-ray for cancer treatment have shown mice with cancerous tumors could be cured by exposure to low-dose radiation. Murphy and Morton [8] treated mice by surgically removing the tumor, irradiated the mice with low-dose radiation before surgically replacing the tumor―50% of these mice would return to perfect health, whereas the other 50% had their cancers return, but slowed 5 times longer than the controls. The control group had their tumors removed and then simply replaced―100% were susceptible for recurrence and quickly. The authors suggested that a second radiation exposure to the treated mice would probably have been sufficient to further prolong or prevent the recurrence of the cancer altogether! Not knowing about radiation hormesis the authors suggest that the immune system could have been “vitally concerned”, but they were “unwilling to commit ourselves… (however, they did say) the results… are strongly suggestive of this.” This revealing study should have naturally led to human experimentation―this was published in 1915―incredibly, it would be 61 years later that this treatment would be attempted on humans.

Low-dose Total-Body Irradiation (TBI) therapy for the treatment of human cancers is the application of low- dose radiation (as opposed to high-dose localized radiation of tumors) in repeated doses over a period of five weeks (Figure 2). Alternatively, TBI can be performed by exposure of half-body irradiation. Either can be performed by exposing the patient to 150r over 5 weeks time, either two times a week in exposures of 15r or three times a week in exposures of 10r [9] [10] .

TBI therapy was first done on humans at Harvard in the 1970s [11] [12] . The Harvard studies treated patients with non-Hodgkins lymphoma who received the standard chemotherapy as well as localized high-dose radiation of tumors but also then got TBI therapy―the 1976 [11] and 1979 [12] studies reported that the low-dose TBI groups increased the four year survival to 70% and 74% vs. the controls at 40% and 52%, respectively.

Sakamoto [13] [14] also reported successful treatment of non-Hodgkins lymphoma in a group of patients who were given up on after standard chemotherapy and high-dose localized radiation. The results in his TBI-treated

patients showed a 100% survival rate after 9 years vs. only 50% in the non-TBI control group. It has been reported that Sakamoto has treated 150 patients during the 1990’s with excellent results including “long-term cures with no symptomatic side effects” [10] .

Richaud [15] reported on 26 patients treated with non-Hodgkins lymphoma by low-dose total-body irradiation followed by radical involved field radiotherapy (IF-RT). After initial TBI therapy, 24 of 26 patients were in complete remission. Following IF-RT, 25 of 26 were in complete remission. At 56 months follow-up, five patients had relapsed and 3 had died indicating at this point an 81% success rate.

Ironically, as it turns out this emerging low dose therapy has actually already been observed to occur in the odd case in patients receiving the standard cancer treatment (high-dose localized radiation). It is a phenomenon referred to as the “abscopal effect”. This is described as “a phenomenon in the treatment of metastatic cancer where localized irradiation of a tumor causes not only a shrinking of the irradiated tumor but also a shrinking of tumors far from the irradiated area. While this phenomenon is extremely rare, its effect on the cancer can be stunning, leading to the disappearance of malignant growths throughout the entire body” [16] .

Recent case studies have discussed this phenomenon, albeit not recognizing that it actually is an inadvertent effect of radiation hormesis. For example, on March 8, 2012 the New England Journal of Medicine [17] published a case of a patient with melanoma who, through the abscopal effect, is having successful treatment results. The patient had advanced stage melanoma that had metastasized to three other sites. The patient was being treated with a new chemotherapy agent, Ipilimumab. To help with pain, they chose to use usual high-dose localized radiation to one of the masses near the spine. They specifically stated “the right hilar lymph-node mass and spleen, which were not the target of radiotherapy, received only low, nontherapeutic doses of radiation (133 cGy and 2.3 cGy, respectively), further supporting the notion that disease regression at these distant sites was due to an enhanced systemic response.”

Unfortunately, the lead author believes this case shows how adding high-dose localized radiation to the immunotherapy drug Ipilimumab in advanced cancers may lead to better results [18] ―instead of considering the more likely reality that it may not have anything to do with the chemo/high-dose radiation combo at all―but only a natural expectation of an immune response from a low-dose stimulation―aka radiation hormesis.

It is forlorn when millions of dollars go towards investigating an immunotherapy drug like Ipilimumab, when its two randomized clinical trials show a survival benefit of 10% [19] and 15%, [20] (Sakamoto’s results show a 9-year 100% survival rate) when low-dose radiation therapy as a stand-alone treatment may prove to be superior to all the current treatments currently used to treat the various cancers as it enhances the immune system offering no significant side effects [10] [21] .

Although TBI therapy remains to be studied in the varied cancer types, it has been shown to be effective in several hundred non-Hodgkins lymphoma patients [11] -[15] as well as in select cases of ovarian, colon, and hematological cancers [10] [13] . As opposed to the standard localized high-dose radiation, TBI therapy seems to physiologically encourage immunopotentiating effects [14] [22] . Overall, TBI therapy seems to be well tolerated, [15] where Sakamoto, one of the pioneers and surviors of this treatment [23] has found the therapy very promising except in the advanced cases and very aged patients [14] .